PMID- 30933891
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20190816
IS  - 1532-2661 (Electronic)
IS  - 0034-5288 (Linking)
VI  - 124
DP  - 2019 Jun
TI  - In-vitro binding analysis of anti-human vascular endothelial growth factor 
      antibodies bevacizumab and aflibercept with canine, feline, and equine vascular 
      endothelial growth factor.
PG  - 233-238
LID - S0034-5288(18)31534-0 [pii]
LID - 10.1016/j.rvsc.2019.03.018 [doi]
AB  - PURPOSE: Promising results have been described for antibodies binding vascular 
      endothelial growth factor (VEGF) in patients with corneal neovascularization. 
      Whether veterinary patients would also benefit from this therapeutic approach has 
      not been investigated yet. We examined binding properties of anti-human VEGF 
      antibodies bevacizumab (Avastin(R)) and aflibercept (Zaltrap(R)) for canine, feline, 
      and equine VEGF. METHODS: Human, equine, feline, and canine VEGF were analyzed 
      for sequence similarity using the "Basic Local Alignment Search Tool" (BLAST). 
      Western-blot analysis and ELISA were used to assess binding properties. RESULTS: 
      BLAST analysis revealed a sequence homology of canine, feline, and equine VEGF to 
      human VEGF-A of 93%, 92%, and 89%, respectively. Western-blot analysis showed 
      immunoreactivity of bevacizumab with human, canine, and feline VEGF, but not with 
      equine VEGF. Aflibercept recognized VEGF of all tested species. ELISA data 
      indicated that bevacizumab and aflibercept bind canine VEGF in a dose-dependent 
      manner. Feline VEGF was bound by bevacizumab and aflibercept in a 
      dose-independent manner. ELISA study further confirmed the lack of bevacizumab 
      binding to equine VEGF, and yielded also a dose-independent binding by 
      aflibercept. CONCLUSIONS: Bevacizumab and aflibercept turned out to bind VEGF 
      with species-specific differences. Further studies are required to investigate 
      their efficacy and safety under clinical conditions.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Muellerleile, Lisa-Marie
AU  - Muellerleile LM
AD  - Department for Companion Animals and Horses, University of Veterinary Medicine 
      Vienna, Austria. Electronic address: lisa-marie.muellerleile@vetmeduni.ac.at.
FAU - Buxbaum, Bernhard
AU  - Buxbaum B
AD  - Department for Companion Animals and Horses, University of Veterinary Medicine 
      Vienna, Austria.
FAU - Nell, Barbara
AU  - Nell B
AD  - Department for Companion Animals and Horses, University of Veterinary Medicine 
      Vienna, Austria. Electronic address: barbara.nell@vetmeduni.ac.at.
FAU - Fux, Daniela A
AU  - Fux DA
AD  - Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, 
      University of Veterinary Medicine Vienna, Austria. Electronic address: 
      daniela.fux@vetmeduni.ac.at.
LA  - eng
PT  - Journal Article
DEP - 20190322
PL  - England
TA  - Res Vet Sci
JT  - Research in veterinary science
JID - 0401300
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 15C2VL427D (aflibercept)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
MH  - Angiogenesis Inhibitors/*metabolism
MH  - Animals
MH  - Bevacizumab/*metabolism
MH  - Blotting, Western
MH  - Cats/*metabolism
MH  - Dogs/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Horses/*metabolism
MH  - Humans
MH  - Protein Binding
MH  - Receptors, Vascular Endothelial Growth Factor/*metabolism
MH  - Recombinant Fusion Proteins/*metabolism
MH  - Vascular Endothelial Growth Factor A/*metabolism
OTO - NOTNLM
OT  - Aflibercept
OT  - Anti-VEGF
OT  - Bevacizumab
OT  - Species cross-reactivity
OT  - VEGF-A
EDAT- 2019/04/02 06:00
MHDA- 2019/08/17 06:00
CRDT- 2019/04/02 06:00
PHST- 2018/08/28 00:00 [received]
PHST- 2019/02/20 00:00 [revised]
PHST- 2019/03/21 00:00 [accepted]
PHST- 2019/04/02 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PHST- 2019/04/02 06:00 [entrez]
AID - S0034-5288(18)31534-0 [pii]
AID - 10.1016/j.rvsc.2019.03.018 [doi]
PST - ppublish
SO  - Res Vet Sci. 2019 Jun;124:233-238. doi: 10.1016/j.rvsc.2019.03.018. Epub 2019 Mar 
      22.